Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Yahoo
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity and epitope demonstrated in several preclinical assays First subject dosed with ORKA-002 expected in Q3 2025 MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing
Finnhub
#64919 Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications ...
Yahoo
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q3 2025, with PK data in 1H 2026 Successful go-public transaction and over $475 million raised in 2024 $
Yahoo
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: TD Cowen’s 45th Annual Health Care ConferenceDate: Tuesday, March 4th, 2025Time: 10:30AM ET Leerink Global Healthcare ConferenceDate: Wednesday, Marc
Yahoo
Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025. On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026. Preclinical data
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | 0.02% | $5.71B | 0.1949% |
EWZS | -0.04% | $129.97M | 0.6% |
EUSB | -0.07% | $684.29M | 0.12% |
FXI | 0.08% | $7.74B | 0.74% |
IBTF | -0.09% | $2.24B | 0.07% |
GXC | 0.10% | $478.20M | 0.59% |
SMMU | 0.12% | $680.09M | 0.35% |
IBMS | -0.15% | $44.14M | 0.18% |
KXI | 0.21% | $711.35M | 0.41% |
FMB | -0.25% | $1.98B | 0.65% |
XONE | -0.26% | $627.32M | 0.03% |
MCHI | 0.28% | $6.46B | 0.59% |
GNMA | 0.29% | $353.00M | 0.1% |
ULST | -0.40% | $586.48M | 0.2% |
CMF | -0.41% | $3.75B | 0.08% |
CMDY | 0.45% | $306.32M | 0.28% |
PDBC | -0.46% | $4.83B | 0.59% |
FLBR | 0.47% | $179.12M | 0.19% |
XHLF | 0.48% | $1.06B | 0.03% |
SPSK | 0.51% | $296.12M | 0.5% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ULTA | -21.60% | $16.67B | -31.25% | 0.00% |
BIRK | -17.10% | $8.59B | -3.20% | 0.00% |
DG | -13.62% | $18.94B | -44.83% | 2.76% |
CBOE | -12.95% | $23.32B | +21.20% | 1.08% |
DLTR | -11.81% | $15.65B | -45.36% | 0.00% |
TR | -11.47% | $2.24B | +0.68% | 1.15% |
CNNE | -10.92% | $1.16B | -16.73% | 2.56% |
RPRX | -10.69% | $13.59B | +3.29% | 2.75% |
BNED | -10.43% | $343.94M | -86.05% | 0.00% |
JNJ | -10.13% | $394.52B | +3.49% | 3.02% |
COTY | -9.94% | $4.75B | -54.43% | 0.00% |
HRL | -9.92% | $16.70B | -12.98% | 3.72% |
PG | -9.84% | $394.01B | +3.56% | 2.40% |
CPB | -9.69% | $11.84B | -10.64% | 3.74% |
DDS | -9.45% | $5.71B | -19.48% | 0.21% |
WBA | -9.37% | $9.68B | -48.41% | 6.71% |
AGL | -9.31% | $1.85B | -26.39% | 0.00% |
MNST | -9.25% | $56.31B | -2.40% | 0.00% |
K | -9.25% | $28.47B | +43.95% | 2.75% |
JWN | -9.08% | $4.08B | +20.67% | 3.11% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VNDA | 38.86% | $273.50M | +14.11% | 0.00% |
SNDL | 35.90% | $373.09M | -27.68% | 0.00% |
ABUS | 31.79% | $663.22M | +35.66% | 0.00% |
GHM | 28.58% | $316.95M | +6.56% | 0.00% |
AG | 28.22% | $3.27B | +14.97% | 0.28% |
FSM | 27.63% | $1.88B | +64.08% | 0.00% |
TLRY | 27.06% | $621.38M | -73.17% | 0.00% |
PLAY | 26.00% | $726.55M | -69.86% | 0.00% |
GRWG | 25.55% | $66.00M | -61.19% | 0.00% |
TGS | 25.38% | $1.90B | +80.60% | 0.00% |
GE | 25.29% | $214.53B | +42.78% | 0.75% |
PARA | 24.86% | $7.75B | -1.78% | 1.74% |
WT | 24.38% | $1.32B | -2.50% | 1.35% |
NOK | 24.13% | $27.99B | +47.18% | 2.68% |
CRNX | 23.78% | $3.23B | -25.81% | 0.00% |
DYN | 23.69% | $1.30B | -59.67% | 0.00% |
NNE | 23.25% | $992.44M | +569.25% | 0.00% |
NOAH | 23.03% | $679.69M | -1.15% | 10.78% |
HIPO | 22.38% | $651.87M | +42.26% | 0.00% |
SPOT | 22.21% | $112.35B | +112.64% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMMP | 0.01% | $270.74M | -20.17% | 0.00% |
COLM | -0.01% | $4.17B | -7.24% | 1.60% |
CWT | 0.02% | $2.87B | +3.90% | 2.35% |
PRI | -0.04% | $9.42B | +12.01% | 1.28% |
REPX | -0.04% | $623.65M | -12.12% | 5.15% |
WCN | -0.06% | $49.77B | +12.10% | 0.62% |
JBSS | -0.06% | $824.09M | -31.64% | 1.21% |
JAZZ | 0.07% | $7.47B | +2.08% | 0.00% |
UVV | -0.07% | $1.38B | +8.35% | 5.73% |
XPEV | 0.08% | $15.26B | +156.51% | 0.00% |
KNSL | 0.08% | $11.22B | -8.12% | 0.13% |
BSY | -0.08% | $12.03B | -23.98% | 0.64% |
CCRN | 0.10% | $492.19M | -19.87% | 0.00% |
AVA | -0.10% | $3.29B | +17.10% | 4.65% |
FIGS | 0.11% | $763.85M | -5.62% | 0.00% |
ZYXI | -0.11% | $71.80M | -81.81% | 0.00% |
ARIS | 0.12% | $984.28M | +124.59% | 1.44% |
ETR | -0.14% | $36.36B | +59.75% | 4.82% |
EGHT | -0.14% | $262.07M | -26.30% | 0.00% |
AMWL | 0.15% | $122.07M | -51.77% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -14.33% | $195.31M | 0.85% |
TAIL | -12.39% | $84.36M | 0.59% |
BTAL | -10.94% | $393.05M | 1.43% |
FLDR | -10.03% | $772.60M | 0.15% |
UUP | -9.82% | $328.64M | 0.77% |
BIL | -9.81% | $41.05B | 0.1356% |
UNG | -8.65% | $413.30M | 1.06% |
USDU | -7.98% | $213.62M | 0.5% |
OWNS | -7.62% | $133.85M | 0.3% |
BNO | -7.38% | $96.15M | 1% |
BSSX | -7.31% | $75.21M | 0.18% |
TFLO | -7.24% | $6.75B | 0.15% |
DBE | -6.82% | $54.74M | 0.77% |
XBIL | -6.54% | $711.70M | 0.15% |
NFLT | -6.48% | $240.73M | 0.5% |
USO | -6.46% | $947.20M | 0.6% |
JMST | -5.86% | $3.55B | 0.18% |
SHYD | -5.80% | $318.07M | 0.35% |
CANE | -5.65% | $11.09M | 0.29% |
SGOV | -5.62% | $39.32B | 0.09% |
Current Value
$12.001 Year Return
Current Value
$12.001 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 32.15% | $293.87M | 0% |
QQA | 24.97% | $176.36M | 0% |
CPRJ | 24.92% | $48.81M | 0.69% |
XBI | 22.11% | $5.45B | 0.35% |
BTC | 21.66% | $3.28B | 0.15% |
PTH | 21.15% | $112.97M | 0.6% |
HEQT | 21.08% | $411.73M | 0.44% |
SLVP | 20.38% | $266.22M | 0.39% |
ETH | 20.12% | $1.29B | 0% |
EZET | 20.08% | $23.66M | 0% |
ETHW | 19.77% | $191.08M | 0% |
ETHA | 19.77% | $2.39B | 0.25% |
ETHV | 19.75% | $92.70M | 0% |
FETH | 19.74% | $797.01M | 0.25% |
CETH | 19.74% | $9.24M | 0% |
EFAA | 19.72% | $101.32M | 0% |
IWO | 19.68% | $11.10B | 0.24% |
QETH | 19.59% | $15.06M | 0.25% |
XSD | 19.47% | $1.09B | 0.35% |
GRID | 19.39% | $2.06B | 0.57% |